Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation

Pancreatic cancer has a dismal prognosis and only a few treatment options are available. In the European Union, pancreatic cancer classifies as a rare disease, allowing drug developers to apply for orphan medicinal product (OMP) designation. The aim of this study was to provide more detail on OMPs f...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulder, Jorn, van Rossum, Tobias, Mariz, Segundo, Magrelli, Armando, de Boer, Anthonius, Pasmooij, Anna M. G., Stoyanova-Beninska, Violeta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720999/
https://www.ncbi.nlm.nih.gov/pubmed/34988030
http://dx.doi.org/10.3389/fonc.2021.809035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720999/
https://www.ncbi.nlm.nih.gov/pubmed/34988030
http://dx.doi.org/10.3389/fonc.2021.809035

Ejemplares similares